FDA Approves Alzheimer’s Drug Despite Expert Panel’s Objections


Sumary of FDA Approves Alzheimer’s Drug Despite Expert Panel’s Objections:

  • Food and Drug Administration on Monday, despite opposition from the agency’s own independent advisory committee and some experts who said there wasn’t enough proof the drug could actually help patients..
  • In clinical trials, aducanumab (Aduhelm) showed a 22% reduction in the development of thinking and memory problems associated with Alzheimer’s disease, according to a statement from the Alzheimer’s Association..
  • However, Monday’s approval flies in the face of a near-unanimous recommendation against use of the drug by the FDA’s own independent advisory committee, as well the objections of a number of prominent Alzheimer’s experts..
  • Back in November, 10 of 11 members on an FDA advisory panel voted against approval, even after hearing a presentation by the agency’s director of neuroscience arguing there is “strong”.
  • Caleb Alexander, an FDA advisory committee member with the Johns Hopkins Bloomberg School of Public Health in Baltimore, told the Times….

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.